Comparative trial of cefuroxime 250 mg with probenecid 250 mg with cefuroxime 500 mg in lower respiratory tract infection Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001
Efficacy and safety of oral pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily versus oral amoxicillin/clavulanate 1000/125 mg three times daily for the treatment of bacterial community-acquired pneumonia (CAP) Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001
Pharmacokinetics and pharmacodynamics of newer fluoroquinolones in patients with lower respiratory tract infections Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012
No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo Source: Eur Respir J 2003; 22: Suppl. 45, 335s Year: 2003
3-day azithromycin (AZM) 500 mg qd versus 10-day clarithromycin (CLA) 500 mg bid for acute exacerbation of chronic bronchitis (AECB) in adults Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002
Treatment of respiratory tract infections: comparison of telithromycin and azithromycin Source: Eur Respir J 2004; 24: Suppl. 48, 638s Year: 2004
Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
Population pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Five-day telithromycin is as effective as 10-day clarithromycin in the treatment of acute exacerbations of chronic bronchitis Source: Eur Respir J 2003; 22: Suppl. 45, 351s Year: 2003
Pharmacokinetics of 14 C-ciclesonide after oral and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002
A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic pseudomonas aeruginosa lung infection Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009
Efficacy and safety of Cefdinir in lower respiratory tract infections Source: Eur Respir J 2002; 20: Suppl. 38, 420s Year: 2002
Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005
Population pharmacokinetics and pharmacodynamics analysis of vancomycin in patients with severe lower respiratory tract gram-positive infections Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014
Efficacy of sequential intravenous (i.v. ) to oral (p.o. ) moxifloxacin in hospitalized patients with community-acquired pneumonia (CAP) due to m. pneumoniae or chlamydia spp. Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
Effect of oral guaifenesin (Mucinex 1200mg) on mucociliary clearance from the lungs of healthy non-smoking adults Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Immunomodulatory effects of moxifloxacin in human respiratory tract infection Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Safety and pharmacokinetics of multiple-dose ciprofloxacin dry powder for inhalation in patients with moderate or severe COPD Source: Annual Congress 2011 - Role of infection in exacerbations of COPD Year: 2011
Pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single, oral dose of 500µg roflumilast in the morning versus evening Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=229 Year: 2004